Partial Epigenetic Reprogramming

Rewinding a cell's biological age without erasing what it is.

Every cell carries an epigenetic 'age' — a pattern of chemical marks on DNA that drifts as we get older. In 2006 Shinya Yamanaka showed four factors (OSKM) can wipe that pattern entirely, turning an adult cell back into a stem cell. Partial reprogramming is the controlled version: deliver those factors briefly, reset the age marks, but stop before the cell forgets its identity.

In animals this has restored vision in aged optic nerves and rejuvenated multiple tissues. The prize is a genuine reversal of aging biology; the danger is dialing too far and triggering cancer or loss of function. The whole field is a race for safer factor combinations and tighter dosing control.

How it works in depth

Partial epigenetic reprogramming aims to restore a youthful pattern of gene expression in old or damaged cells without turning them into stem cells. The classic recipe is the four Yamanaka factors (Oct4, Sox2, Klf4, c-Myc, or OSKM) that Shinya Yamanaka showed can convert adult cells into induced pluripotent stem cells. The rejuvenation field deliberately stops short of that endpoint. Most programs deliver only three factors (OSK), omitting the oncogene c-Myc, and express them transiently or in pulses so the cell's epigenetic clock winds back while its identity, function, and tissue role are preserved. Mechanistically, the factors are thought to reset DNA methylation marks and chromatin state, reversing some of the drift that accumulates with age. The central safety concern is dose and duration: continuous OSKM expression can produce teratomas and loss of cell identity, whereas brief or cyclic induction has improved regeneration and, in some mouse studies, extended lifespan without observed tumors.

Where the field is in 2025-2026

The headline milestone is regulatory. In January 2026, Life Biosciences announced FDA clearance of its IND for ER-100, widely described as the first partial-reprogramming cellular rejuvenation therapy cleared for human trials. The Phase 1 first-in-human study (reportedly NCT07290244) plans to enroll patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), delivering OSK intravitreally to retinal ganglion cells. The company presented supporting nonhuman-primate and liver/ocular data at ARDD 2025 and AAO. Key open debates remain: how to control dose and avoid oncogenic risk, whether epigenetic-clock changes reflect genuine functional rejuvenation, and how to deliver factors safely beyond the relatively immune-privileged eye.

Leading programs & players

Altos Labs, launched in 2022 with roughly $3 billion and Yamanaka as an advisor, made scientific progress in 2025 (including a Cell paper on mesenchymal drift and Joan Mannick's CMO appointment) but reportedly had no disclosed clinical program as of late 2025. Retro Biosciences, backed by Sam Altman, was reportedly raising a large Series A and targeting an early human trial. NewLimit, co-founded by Brian Armstrong, closed a reported $130 million Series B in 2025 and is advancing a liver (hepatocyte) reprogramming candidate. Others exploring the space include Shift Bioscience, YouthBio Therapeutics, AgeX, and Calico. The market outlook is high-risk, high-reward: enormous private capital, an unproven but rapidly de-risking modality, and a first clinical readout that could validate or sober the entire thesis.

FAQ

Is partial epigenetic reprogramming the same as making stem cells?

No. It uses some of the same Yamanaka factors but stops short of full pluripotency, aiming to reset a cell's age while keeping its identity and function intact.

Has partial reprogramming been tested in humans?

Life Biosciences received FDA clearance for its ER-100 IND in January 2026, reportedly the first partial-reprogramming therapy cleared for a human trial, targeting optic neuropathies. Broader human data are not yet available.

What is the main safety risk?

Uncontrolled or continuous expression of reprogramming factors can cause tumors (teratomas) and loss of cell identity. Programs mitigate this by omitting c-Myc and using transient or cyclic dosing.

Which companies lead the field?

Life Biosciences, Altos Labs, Retro Biosciences and NewLimit are among the most prominent, alongside Shift Bioscience, YouthBio Therapeutics, AgeX and Calico.

Companies working on Partial Epigenetic Reprogramming

Explore the interactive landscapes →